Author:
Wang Yumin,Wu Shuang,Li Qiang,Lang Weihong,Li Wenjing,Jiang Xiaodong,Wan Zhirong,Chen Jichao,Wang Hongquan
Abstract
Epigallocatechin 3-gallate (EGCG), an abundant polyphenolic component derived from green tea extract, possesses versatile bioactivities that can combat many diseases. During the last decade, EGCG was shown to be effective in experimental models of Parkinson’s disease (PD). Several experimental studies have suggested that it has pleiotropic neuroprotective effects, which has enhanced the appeal of EGCG as a therapeutic strategy in PD. In this review, we compiled recent updates and knowledge of the molecular mechanisms underlying the neuroprotective effects of EGCG in PD. We focused on the effects of EGCG on apoptosis, oxidative stress, inflammation, ferroptosis, modulation of dopamine production, and the aggregation of α-synuclein. The review highlights the pharmacological features of EGCG and its therapeutic implications in PD. Taken together, the accumulated data indicate that EGCG is a promising neuroprotective compound for the treatment of PD.
Funder
National Natural Science Foundation of China
Subject
Pharmacology (medical),Pharmacology
Reference119 articles.
1. Cognitive decline in Parkinson disease;Aarsland;Nat. Rev. Neurol.,2017
2. Parkinsonism genes: Culprits and clues;Abeliovich;J. Neurochem.,2006
3. Effect of epigallocatechin-3-gallate on inflammatory mediators release in LPS-induced Parkinson's disease in rats;Al-Amri;Indian J. Exp. Biol.,2013
4. Epigallocatechin 3-gallate: From green tea to cancer therapeutics.;Alam;Food Chem.,2022
5. Alpha synuclein aggregation drives ferroptosis: An interplay of iron, calcium and lipid peroxidation;Angelova;Cell Death Differ.,2020
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献